Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446024 | 0.95 | MEN1 (0.52) | HRH3MEN1KMT2AMAPTLMNA | |
| SCHEMBL1446415 | 0.90 | HRH3 (0.43) | HRH3MEN1KMT2AMAPTLMNA | |
| SCHEMBL1447099 | 0.86 | MEN1 (0.52) | HRH3MEN1KMT2AMAPTLMNA | |
| SCHEMBL1446211 | 0.85 | HRH3 (0.45) | HRH3MEN1KMT2AMAPTLMNA | |
| SCHEMBL1445899 | 0.84 | HRH3 (0.50) | HRH3MEN1KMT2AMAPTLMNA | |
| SCHEMBL1445984 | 0.81 | CYP1A2 (0.53) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL1447101 | 0.78 | MAPT (0.47) | HRH3MEN1KMT2AMAPTLMNA | |
| SCHEMBL1446068 | 0.77 | HRH3 (0.45) | HRH3MEN1KMT2AMAPTLMNA | |
| SCHEMBL1446414 | 0.75 | HRH3 (0.43) | HRH3MEN1KMT2AMAPTLMNA | |
| SCHEMBL1446027 | 0.75 | MEN1 (0.49) | HRH3MEN1KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910743-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-03-22 | — | — | US | claimed |
| US-20090324511-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-12-31 | — | — | US | claimed |
| US-20070066626-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-03-22 | — | — | US | claimed |
| US-7910743-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090324511-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7538223-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20070066626-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324511-A1 | Compounds, Compositions and Methods | TNNI3, TNNC1, TNNT2 | HRH3 3208/4885MEN1 4344/4885KMT2A 4396/4885 |
| US-20070066626-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | HRH3 3208/4885MEN1 4344/4885KMT2A 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.